BioGeneration Ventures
Stan van Boeckel is Professor of Medicinal Chemistry at Leiden University and CSO of Pivot Park in Oss. He has broad experience in drug discovery, both in the pharmaceutical industry (1982-2011) and at the university (1989-today). Stan van Boeckel was head of Lead Discovery and Medicinal Chemistry at Organon (later Schering Plough and MSD). Under his supervision the antithrombotic drug and first selective factor Xa inhibitor fondaparinux (Arixtra®) was discovered as well as the btk inhibitor and anti-cancer drug acalabrutinib (Calquence®), both of which are FDA approved. In addition, several other new chemical entities from his group passed phase 1 clinical trials. Professor van Boeckel is an advisor to five life sciences companies.
During his career, Stan Van Boeckel co-authored over 200 manuscripts and patents and received several awards, including the Unilever Chemistry Award, the AKZO-Chemistry Award, the Golden Medal of the Royal Dutch Chemical Society, the International Carbohydrate (Whistler) Award and the Lemieux Award on Biotechnology.
He completed his PhD (cum laude) in 1982 at Leiden University in the field of Bio-Organic Chemistry.
This person is not in the org chart
This person is not in any offices
BioGeneration Ventures
BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech, medtech, and diagnostics companies. BGV has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €100 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together.